CellCarta and Imagene AI announced an expanded collaboration on October 1, 2026, to provide biopharma companies a coordinated path for validating, deploying and scaling AI-powered biomarker and companion diagnostic (CDx) programs, and said work is already underway with two global pharmaceutical companies. The expanded collaboration is meant to carry programs from biomarker strategy and assay development through validation, clinical trial execution, regulatory readiness and deployment, the…
This article has been indexed from Unite.AI
Read the original article: